Dalmark M, Pals H, Johnsen A H
Department of Oncology, Finsen Institute, Rigshospitalet, Copenhagen, Denmark.
Acta Oncol. 1991;30(1):23-6. doi: 10.3109/02841869109091808.
The possibility that verapamil might increase the sensibility of colorectal carcinomas to doxorubicin was studied in 24 patients without previous cytotoxic chemotherapy. The treatment started with oral verapamil, which was escalated up to the individual maximum tolerable dose (defined by prolongation of P-Q in ECG, fall in blood pressure, or dizziness). The median maximum tolerable dose was 600 mg (range 320-1,440 mg). During continued verapamil administration the patients then got weekly infusions of doxorubicin, 25 mg/m2. The median number of doxorubicin courses was 8 (range 2-22). Among 21 patients evaluable for response and toxicity two partial remissions occurred but no complete remission. The study did not indicate enhanced cardiac, hematological or non-hematological toxicity from the combined treatment.
在24例未曾接受过细胞毒性化疗的患者中，研究了维拉帕米是否可能增加结肠直肠癌对阿霉素的敏感性。治疗从口服维拉帕米开始，剂量逐渐增加至个体最大耐受剂量（通过心电图P-Q间期延长、血压下降或头晕来定义）。最大耐受剂量的中位数为600毫克（范围为320 - 1440毫克）。在持续给予维拉帕米期间，患者随后每周输注阿霉素，剂量为25毫克/平方米。阿霉素疗程的中位数为8次（范围为2 - 22次）。在21例可评估反应和毒性的患者中，出现了2例部分缓解，但无完全缓解。该研究未表明联合治疗会增强心脏、血液学或非血液学毒性。
